MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
Status
RECRUITING
Phase
NA
Age
≥ 18 Years
Enrollments
180Conditions
Prostate Cancer, Prostate Adenocarcinoma, Prostate NeoplasmSummary
Doctors leading this study hope to learn about a software that researchers at the University of Chicago have developed to help analyze radiographic images (different techniques for taking images that allow doctors to visualize the body's internal structures) of the prostate. Participation in this research will last about 12 months. There is a one-time MRI and 1-2 biopsies and then the investigator would like to follow the participant's progress.
Locations
1 location Found with status Recruiting
Status
- RECRUITING
Contact Person
- Cancer Intake Team
- 855-702-8222
- [email protected]
Study Chair
- Aytekin Oto, MD
Eligibility Criteria
Inclusion Criteria:
* Patients with known or suspected prostate cancer who have been referred for a diagnostic magnetic resonance imaging (MRI) exam of the prostate, to be followed by an MRI-guided fusion biopsy of the prostate.
* Voluntary written informed consent before the MRI examination.
Exclusion Criteria:
* Subjects incapable of giving informed written consent.
* Subjects who cannot adhere to the experimental protocols for any reason, or have an inability to communicate with the researcher;
* Subjects with psychiatric disorders that affect their ability to consent for themselves will be excluded and not the entire population of patients with psychiatric disorders.
* Prisoners.
* Minor children (under the age of 18 years old).
* Patients with previous treatments (surgery, radiation, focal ablation, hormone or other chemotherapy) for prostate cancer.
Study Plan
All Participants (Single Arm)
EXPERIMENTAL
All participants in this trial will be provided with routine instructions and precaution information before starting the magnetic resonance (MRI) scan. After the MRI, participants will undergo an MRI-guided fusion biopsy of the prostate as ordered by their doctor. During this prostate MRI-guided fusion biopsy, the research team will obtain tissue from up to two additional biopsy targets selected by the Risk Map DSS tool. Ultimately, the clinical radiologist will make the final decision on the targets to be biopsied.
OTHER:
Risk Map Decision Support System (DSS).Description:
The Risk Map DSS tool is an image analysis software that automatically interprets images of the prostate that were captured using an MR (magnetic resonance) scanner (an imaging technique that uses scanners to take pictures of the body). This tool can potentially identify additional areas of cancer in your prostate that may have otherwise been missed.RADIATION:
Magnetic Resonance Imaging (MRI)Description:
A medical imaging test that uses a large machine/scanner to take images of the body and internal organs and structures.PROCEDURE:
Magnetic Resonance Imaging (MRI) Guided BiopsyDescription:
A removal of tumor tissue from the body based on images of the prostate provided by a previous magnetic resonance imaging (MRI) test. Up to 2 biopsies on trial.
Outcome Measures
Primary Outcome Measures
Decision Map Tool Compared to Oncologists
Timeline
Last Updated
July 31, 2024Start Date
February 2, 2023Today
May 12, 2025Completion Date ( Estimated )
May 1, 2026
Sponsors of this trial
Lead Sponsor
University of Chicago
RECRUITING 
≥ 18 Years